Abstract
Sardinian population can be instrumental in defining the molecular basis of cancer, using the identity-by-descent method. We selected seven Sardinian breast cancer families originating from the northern-central part of the island with multiple affected members in different generations. We genotyped 106 members of the seven families and 20 control nuclear families with markers flanking BRCA2 locus at 13q12–q13. The detection of a common haplotype shared by four out of seven families (60%) suggests the presence of a founder BRCA2 mutation. Direct sequencing of BRCA2 coding exons of patients carrying the shared haplotype, allowed the identification of a ‘frame-shift’ mutation at codon 2867 (8765delAG), causing a premature termination-codon. This mutation was found in breast cancer patients as well as one prostate and one bladder cancer patient with shared haplotype. We then investigated the frequency of 8765delAG in the Sardinian breast cancer population by analysing 270 paraffin-embedded normal tissue samples from breast cancer patients. Five patients (1.7%) were found to be positive for the 8765delAG mutation. Discovery of a founder mutation in Sardinia through the identity-by-descent method demonstrates that this approach can be applied successfully to find mutations either for breast cancer or for other types of tumours. © 2000 Cancer Research Campaign
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Budroni M, Cesaraccio R, Desole MG, Pirino DR, Sechi O, Massarelli G, Tanda F, Manca A, Cossu Rocca P and Cocco L (1998) Incidenza dei tumori nella provincia di Sassari Anni 1992–1994. In: Incidenza e mortalità per tumori nella provincia di Sassari Anni 1992–1994, Budroni M, Tanda F (eds). Tipografia Moderna: Sassari
Claus EB, Risch N and Thompson WD (1991) Genetic analysis of breast cancer in the Cancer and Steroid Hormone Study. Am J Hum Genet 48: 232–242
Couch FJ, Rommens JM, Neuhausen SL, Belanger C, Dumont M, Abel K, Bell R, Berry S, Bogden R, Cannon-Albright L, Farid L, Frye C, Hattier T, Janecki T, Jiang P, Kehrer R, Leblanc JF, McArthur-Morrison J, McSweeney D, Miki Y, Peng Y, Samson C, Schroeder M, Snyder SC, Stringfellow M, Stroup C, Swedlund B, Swensen J, Teng D, Thakur S, Tran T, Tranchant M, Welver-Feldhaus J, Wong AKC, Shizuya H, Labrie F, Skolnick MH, Goldgar DE, Kamb A, Weber BL, Tavtigian SV and Simard J (1996) Generation of an integrated transcription map of the BRCA2region on chromosome 13q12–q13. Genomics 36: 86–99
De Benedetti VMG, Radice P, Mondini P, Spatti G, Conti A, Illeni MT, Caligo MA, Cipollini G, Bevilaqua G, Pilotti S and Pierotti MA (1996) Screening for mutations in exon 11 of the BRCA1 gene in 70 Italian breast and ovarian cancer patients by protein truncation test. Oncogene 13: 1353–1357
Easton DF, Bishop DT, Ford D and Crockford GP the Breast Cancer Linkage Consortium (1993) Genetic linkage analysis in familial breast and ovarian cancer: results from 214 families. Am J Hum Genet 52: 678–701
Easton DF, Ford D and Bishop DT the Breast Cancer Linkage Consortium (1995) Breast and ovarian cancer incidence in BRCA1 -mutation carriers. Am J Hum Genet 56: 265–271
Easton DF, Steele L, Fields P, Ormiston W, Averill D, Daly PA, McManus R, Neuhausen SL, Ford D, Wooster R, Cannon-Albright LA, Stratton MR and Goldgar DE (1997) Cancer risks in two large breast cancer families linked to BRCA2 on chromosome 13q12–13. Am J Hum Genet 61: 120–128
Ford D, Easton DF, Bishop DT, Narod SA and Goldgar DT the Breast Cancer Linkage Consortium (1994) Risks of cancer in BRCA1 mutation carriers. Lancet 343: 692–695
Gayther SA, Mangion J, Russel P, Seal S, Barfoot R, Ponder BAJ, Stratton MR and Easton D (1997) Variation of risks of breast and ovarian cancer associated with different germline mutations of the BRCA2 gene. Nat Genet 15: 103–105
Gudmundsson J, Johannesdottir G, Arason A, Bergthorsson JT, Ingvarsson S, Egilsson V and Barkadottir RB (1996) Frequent occurrence of BRCA2 linkage in Icelandic breast cancer families and segregation of a common BRCA2 haplotype. Am J Hum Genet 58: 749–756
Jackson DP, Quirke P, Lewis F, Boylston AW, Sloan JM, Robertson D and Taylor GR (1989) Detection of measles virus RNA in paraffin-embedded tissue. Lancet 17: 1391
Johannesdottir G, Gudmundsson J, Bergthorsson JT, Arason A, Agnarsson BA, Eiriksdottir G, Johannsson OT, Borg A, Ingvarsson S, Easton DF, Egilsson V and Barkardottir RB (1996) High prevalence of the 999del5 mutation in icelandic breast and ovarian cancer patients. Cancer Res 56: 3663–3665
Lerer I, Wang T, Peretz T, Sagi M, Kaduri L, Orr-Urtreger A, Stadler J, Gutman H and Abeliovich D (1998) The 8765delAG mutation in BRCA2 is common among Jews of Yemenite extraction. Am J Hum Genet 63: 274–279
Miki Y, Swensen J, Schattuck-Eidens D, Futreal PA, Harshman K, Tavtigian S, Liu QY, Cochran C, Bennet LM, Ding W, Bell R, Rosenthal J, Hussey C, Tran T, McClure M, Frye C, Hattier T, Phelps R, Haugen-Strano A, Katcher H, Yakumo K, Gholami Z, Shaffer D, Stone S, Bayer S, Wray C, Bogden R, Dayananth P, Ward J, Tonin P, Narod S, Bristow PK, Norris FH, Helvering L, Morrison P, Rosteck P, Lai M, Barret JC, Lewis C, Neuhausen S, Cannon-Albright L, Goldgar D, Wiseman R, Kamb A and Skolnick MH (1994) A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 266: 66–71
Montagna M, Santacatterina M, Corneo B, Menin C, Serova O, Lenoir GM, Chieco-Bianchi L and D'Andrea E (1996) Identification of seven new BRCA1 germline mutations in Italian breast and breast/ovarian cancer families. Cancer Res 56: 5466–5469
Narod SA, Ford D, Devilee P, Barkadottir RB, Lynch HT, Smith SA, Ponder BA, Weber BL, Garber JE, Birch JM, Cornelis RS, Kelsell DP, Spurr NK, Smyth E, Haites N, Sobol H, Bignon Y-J, Chang-Claude J, Hamann U, Lindblom A, Borg A, Piver MS, Gallion HH, Struewing JP, Whittemore A, Tonin P, Goldgar DE and Easton DF the Breast Cancer Linkage Consortium (1995) An evaluation of genetic heterogeneity in 145 breast-ovarian cancer families. Am J Hum Genet 56: 254–264
Neuhausen SL, Godwin AK, Gershoni-Baruch R, Schubert E, Garber J, Stoppa-Lyonnet D, Olah E, Csokay B, Serova O, Lalloo F, Osorio A, Stratton M, Offit K, Boyd J, Caligo MA, Scott RJ, Schofield A, Teugels E, Schwab M, Cannon-Albright L, Bishop T, Easton D, Benitez J, King MC, Ponder BAJ, Weber B, Devilee P, Borg A, Narod SA and Goldgar D (1998) Haplotype and phenotype analysis of nine recurrent BRCA2 mutations in 111 families: results of an international study. Am J Hum Genet 62: 1381–1388
Phelan CM, Lancaster JM, Tonin P, Gumbs C, Cochran C, Carter R, Ghadirian P, Perret C, Moslehi R, Dion F, Faucher MC, Dole K, Karimi S, Foulkes W, Lounis H, Warner E, Goss P, Anderson D, Larsson C, Narod SA and Futreal PA (1996) Mutation analysis of the BRCA2 gene in 49 site-specific breast cancer families. Nat Genet 13: 120–122
Pirastu M, Galanello R, Doherty MA, Tuveri T, Cao A and Kan YW (1987) The same β-globin gene mutation is present on nine different β-thalassemia chromosomes in a Sardinian population. Proc Natl Acad Sci USA 84: 2882–2885
Roa BB, Boyd AA, Volcik K and Richards CS (1996) Ashkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2. Nat Genet 14: 185–187
Sambrook J, Fritsch EF and Maniatis T (1989). Molecular Cloning: A Laboratory Manual. Cold Spring Harbor Laboratory Press: Cold Spring Harbor
Serova OM, Mazoyer S, Puget N, Dubois V, Tonin P, Shugart YY, Goldgar D, Narod SA, Lynch HT and Lenoir GM (1997) Mutations in BRCA1 and BRCA2 in breast cancer families: are there more breast cancer-susceptibility genes?. Am J Hum Genet 60: 486–495
Stratton MR, Ford D, Neuhausen S, Seal S, Wooster R, Friedman LS, King M-C, Egilsson V, Devilee P, McManus R, Daly PA, Smyth E, Ponder BAJ, Peto J, Cannon-Albright L, Easton DF and Goldgar DE (1994) Familial male breast cancer is not linked to BRCA1. Nat Genet 7: 103–107
Szabo CI and King MC (1997) Population genetics of BRCA1 and BRCA2. Am J Hum Genet 60: 1013–1102
Tavtigian SV, Simard J, Rommens J, Couch F, Shattuck-Eidens D, Neuhausen S, Merajver S, Thorlacius S, Offit K, Stoppa-Lyonnet D, Belanger C, Bell R, Berry S, Bogden R, Chen Q, Davis T, Dumont M, Frye C, Hattier T, Jammulapati S, Janecki T, Jiang P, Keher R, Leblanc J-F, Mitchell JT, McArthur-Morrison J, Nguyen K, Peng Y, Samson C, Schroeder M, Snyder SC, Steele L, Stringfellow M, Stroup C, Swedlund B, Swensen J, Teng D, Thomas A, Tran T, Tranchant M, Weaver-Feldhaus J, Wong AKC, Shizuya H, Eyfiord J, Cannon-Albright L, Labrie F, Skolnick MH, Weber B, Kamb A and Goldgar DE (1996) The complete gene and mutations in chromosome 13q-linked kindreds. Nat Genet 12: 333–337
Thorlacius S, Tryggvadottir L, Olafsdottir GH, Jonasson JG, Ogmundsdottir HM, Tulinius H and Eyfjord JE (1996) A single BRCA2 mutation in male and female breast cancer families from Iceland with varied cancer phenotypes. Nat Genet 13: 117–119
Tonin PN, Mes-Masson AM, Futreal PA, Morgan K, Mahon M, Foulkes WD, Cole DEC, Provencher D, Ghadirian P and Narod SA (1998) Founder BRCA1 and BRCA2 mutations in French Canadian breast and ovarian cancer families. Am J Hum Genet 63: 1341–1351
Vehmanen P, Friedman LS, Eerola H, Sarantaus L, Pyrhönen S, Ponder B, Muhonen T and Nevanlinna H (1997 a) A low proportion of BRCA2 mutations in Finnish breast cancer families. Am J Hum Genet 60: 1050–1058
Vehmanen P, Friedman LS, Eerola H, McClure M, Ward B, Sarantaus L, Kainu T, Syrjäkoski K, Pyrhönen S, Kallioniemi OP, Muhonen T, Luce M, Frank TS and Nevanlinna H (1997 b) Low proportion of BRCA1 and BRCA2 mutations in Finnish breast cancer families: evidence for additional susceptibility genes. Hum Mol Genet 13: 2309–2315
Wooster R, Bignell G, Lancaster J, Swift S, Seal S, Mangion J, Collins N, Gregory S, Gumbs C, Micklem G, Barfoot R, Hamoudi R, Patel S, Rice C, Biggs P, Hashim Y, Smith A, Connor F, Arason A, Gudmundsson J, Ficenec D, Kelsell D, Ford D, Tonin P, Bishop DT, Spurr NK, Ponder BAJ, Eeles R, Peto J, Devilee P, Cornelisse C, Lynch H, Narod S, Lenoir G, Egilsson B, Barkadottir RB, Easton DF, Bentley DR, Futreal PA, Ashworth A and Stratton MR (1995) Identification of the breast cancer susceptibility gene BRCA2. Nature 378: 789–792
Zanetti R, Vercelli M, Crossignani P, Simonato L, Stanta G, Cocconi G, Federico N, Ferretti S, Amadori D, Pannelli F, Buiati E, Conti FMS, Gafà L, Magnani C, Ponz de Leon M and Picci P (1997) Cancer in Italy. Incidence Data from Cancer Registries, vol. 2: 1988–1992, Zanetti R, Crosignani P, Rosso S (eds). I1 Pensiero Scientifico Editore: Roma
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Pisano, M., Cossu, A., Persico, I. et al. Identification of a founder BRCA2 mutation in Sardinia. Br J Cancer 82, 553–559 (2000). https://doi.org/10.1054/bjoc.1999.0963
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1054/bjoc.1999.0963
Keywords
This article is cited by
-
Founder BRCA1/2 mutations in the Europe: implications for hereditary breast-ovarian cancer prevention and control
EPMA Journal (2010)
-
A role of BRCA1 and BRCA2germline mutations in breast cancer susceptibility within Sardinian population
BMC Cancer (2009)
-
Founder mutations account for the majority of BRCA1-attributable hereditary breast/ovarian cancer cases in a population from Tuscany, Central Italy
Breast Cancer Research and Treatment (2009)
-
BRCA1/BRCA2 mutation status and clinical-pathologic features of 108 male breast cancer cases from Tuscany: a population-based study in central Italy
Breast Cancer Research and Treatment (2009)
-
Origin and distribution of the BRCA2-8765delAG mutation in breast cancer
BMC Cancer (2007)